



## Announcement Summary

**Entity name**

TELIX PHARMACEUTICALS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Wednesday October 29, 2025

**The +securities to be quoted are:**

Other

**Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.**

Issue of Telix ordinary shares to Dedicaid GmbH sellers following satisfaction of an agreed contractual milestone related to regulatory approval of the purchased clinical decision support software AI platform. Refer ASX release dated 27 April 2023.

**Total number of +securities to be quoted**

<b>ASX +security code</b>	<b>Security description</b>	<b>Number of +securities to be quoted</b>	<b>Issue date</b>
TLX	ORDINARY FULLY PAID	24,219	29/10/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

**1.2 Registered number type**

ACN

**Registration number**

616620369

**1.3 ASX issuer code**

TLX

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

29/10/2025



## Part 2 - Type of Issue

---

### **2.1 The +securities to be quoted are:**

Other

**Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.**

### **2.2 The +class of +securities to be quoted is:**

Additional +securities in a class that is already quoted on ASX ("existing class")

### **2.3c Have these +securities been offered under a +disclosure document or +PDS?**

No

**2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

Issue of Telix ordinary shares to Dedicaid GmbH sellers following satisfaction of an agreed contractual milestone related to regulatory approval of the purchased clinical decision support software AI platform. Refer ASX release dated 27 April 2023.

**2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**Additional +securities to be quoted in an existing class**

**ASX +security code and description**

TLX : ORDINARY FULLY PAID

**Issue date**

29/10/2025

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

Issue details

**Number of +securities to be quoted**

24,219

**Are the +securities being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

Telix issued 24,219 ordinary shares equivalent to 220,000 Euros calculated in accordance with agreed formula noted below on satisfaction of a contractual milestone event. Refer ASX release 27/04/23.

**Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted**

16.220500

**Any other information the entity wishes to provide about the +securities to be quoted**

Telix issued 24,219 ordinary shares equivalent to 220,000 Euros on satisfaction of a contractual milestone event calculated by converting WVAP of Telix shares for 10 trading days up to and including 23 October 2025 of \$16.2205 to Euros using the RBA exchange rate on 23 October 2025 (AUD:Euros 0.5600) for a Euro WVAP of 9.0835 euros, and then dividing the 220,000 Euros by the Euro WVAP calculated.

**The purpose(s) for which the entity is issuing the securities**

To pay for the acquisition of an asset

**Please provide additional details**

Partial earn-out payment of total 1.1 million Euros agreed to be paid to the Dedicaid sellers on satisfaction of agreed milestone events. Refer ASX release dated 27 April 2023.



## Part 4 - Issued capital following quotation

**Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLX : ORDINARY FULLY PAID	338,483,042

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,265,004
TLXAO : SHARE APPRECIATION RIGHTS	14,889,282
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	233,397
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	10,561
TLXAV : DEFERRED SHARE RIGHTS US 2024	10,342
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	2,679,246
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	289,225
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000



Part 5 - Other Listing Rule requirements

---

**5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

24,219

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

N/A